PL3416675T3 - Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda - Google Patents
Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambdaInfo
- Publication number
- PL3416675T3 PL3416675T3 PL17753966T PL17753966T PL3416675T3 PL 3416675 T3 PL3416675 T3 PL 3416675T3 PL 17753966 T PL17753966 T PL 17753966T PL 17753966 T PL17753966 T PL 17753966T PL 3416675 T3 PL3416675 T3 PL 3416675T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- virus infection
- hepatitis delta
- delta virus
- interferon lambda
- Prior art date
Links
- 241000724709 Hepatitis delta virus Species 0.000 title 1
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297759P | 2016-02-19 | 2016-02-19 | |
| EP17753966.5A EP3416675B9 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
| PCT/US2017/018466 WO2017143253A1 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3416675T3 true PL3416675T3 (pl) | 2021-10-11 |
Family
ID=59625481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17753966T PL3416675T3 (pl) | 2016-02-19 | 2017-02-17 | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953072B2 (es) |
| EP (2) | EP3957319B1 (es) |
| JP (3) | JP7674628B2 (es) |
| KR (1) | KR20180110127A (es) |
| CN (1) | CN108883156A (es) |
| CY (1) | CY1124220T1 (es) |
| DK (1) | DK3416675T3 (es) |
| ES (2) | ES3008560T3 (es) |
| HR (1) | HRP20210862T1 (es) |
| HU (1) | HUE055343T2 (es) |
| LT (1) | LT3416675T (es) |
| PL (1) | PL3416675T3 (es) |
| PT (1) | PT3416675T (es) |
| RS (1) | RS61944B1 (es) |
| SI (1) | SI3416675T1 (es) |
| SM (1) | SMT202100335T1 (es) |
| WO (1) | WO2017143253A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
| RS61944B1 (sr) | 2016-02-19 | 2021-07-30 | Eiger Biopharmaceuticals Inc | Lečenje infekcije hepatitis delta virusom sa interferonom lambda |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| CN113286605A (zh) * | 2018-08-23 | 2021-08-20 | 艾格尔峰生物制药有限公司 | 用干扰素λ治疗丁型肝炎病毒感染 |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021034101A1 (ko) * | 2019-08-21 | 2021-02-25 | 한국과학기술원 | 신규 인터페론 람다 변이체 및 이의 제조방법 |
| JP2022552001A (ja) * | 2019-10-16 | 2022-12-14 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | Ｄ型肝炎ウイルス感染を処置する方法 |
| EP4100047A4 (en) * | 2020-02-06 | 2024-03-13 | Eiger Biopharmaceuticals, Inc. | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2286128T3 (es) | 2000-06-30 | 2007-12-01 | Zymogenetics, Inc. | Proteina zcyto21 tipo interferon. |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| CA2503305A1 (en) | 2002-10-23 | 2004-05-06 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 |
| CA2520148A1 (en) | 2003-04-01 | 2004-12-23 | Intermune, Inc. | Compositions and methods for treating coronavirus infection and sars |
| JP4808157B2 (ja) | 2003-08-07 | 2011-11-02 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２８およびｉｌ−２９の均一な調製物 |
| AU2005231476B2 (en) | 2004-04-02 | 2011-09-01 | Zymogenetics, Inc. | Il-28 and il-29 cysteine mutants for treating viral infection |
| WO2006076014A2 (en) | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| EP1909821A2 (en) | 2005-07-20 | 2008-04-16 | ZymoGenetics, Inc. | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
| JP2009502803A (ja) | 2005-07-20 | 2009-01-29 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法 |
| JP5364375B2 (ja) | 2005-10-04 | 2013-12-11 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２９の生産および精製の方法 |
| JP2010504909A (ja) | 2006-09-14 | 2010-02-18 | メドジェニクス・メディカル・イスラエル・リミテッド | 長期持続性の医薬製剤 |
| EP2265715B1 (en) | 2008-04-04 | 2016-12-28 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
| WO2011088126A2 (en) * | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
| WO2012131061A1 (en) | 2011-04-01 | 2012-10-04 | Novartis Ag | Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
| EP2720716B1 (en) * | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| EP2748328A4 (en) | 2011-08-25 | 2015-03-04 | Nanogen Pharmaceutical Biotechnology | PEG-INTERFERON LAMBDA 1 CONJUGATES |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| CN104837501B (zh) | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| SG11201503459SA (en) * | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| PL3137078T3 (pl) | 2014-05-01 | 2019-08-30 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP2017536403A (ja) | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
| JP7187315B2 (ja) * | 2015-11-04 | 2022-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | デルタ型肝炎ウイルス感染の処置 |
| RS61944B1 (sr) | 2016-02-19 | 2021-07-30 | Eiger Biopharmaceuticals Inc | Lečenje infekcije hepatitis delta virusom sa interferonom lambda |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| CN113286605A (zh) | 2018-08-23 | 2021-08-20 | 艾格尔峰生物制药有限公司 | 用干扰素λ治疗丁型肝炎病毒感染 |
| US20220387432A1 (en) | 2019-09-19 | 2022-12-08 | Eip Pharma, Inc. | Compositions and methods for treating prion disease |
| EP4100047A4 (en) | 2020-02-06 | 2024-03-13 | Eiger Biopharmaceuticals, Inc. | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA |
-
2017
- 2017-02-17 RS RS20210703A patent/RS61944B1/sr unknown
- 2017-02-17 HU HUE17753966A patent/HUE055343T2/hu unknown
- 2017-02-17 ES ES21164362T patent/ES3008560T3/es active Active
- 2017-02-17 SI SI201730795T patent/SI3416675T1/sl unknown
- 2017-02-17 ES ES17753966T patent/ES2874592T3/es active Active
- 2017-02-17 EP EP21164362.2A patent/EP3957319B1/en active Active
- 2017-02-17 JP JP2018543599A patent/JP7674628B2/ja active Active
- 2017-02-17 WO PCT/US2017/018466 patent/WO2017143253A1/en not_active Ceased
- 2017-02-17 SM SM20210335T patent/SMT202100335T1/it unknown
- 2017-02-17 DK DK17753966.5T patent/DK3416675T3/da active
- 2017-02-17 LT LTEP17753966.5T patent/LT3416675T/lt unknown
- 2017-02-17 KR KR1020187026586A patent/KR20180110127A/ko not_active Ceased
- 2017-02-17 US US15/999,239 patent/US10953072B2/en active Active
- 2017-02-17 CN CN201780020097.4A patent/CN108883156A/zh active Pending
- 2017-02-17 PL PL17753966T patent/PL3416675T3/pl unknown
- 2017-02-17 HR HRP20210862TT patent/HRP20210862T1/hr unknown
- 2017-02-17 EP EP17753966.5A patent/EP3416675B9/en active Active
- 2017-02-17 PT PT177539665T patent/PT3416675T/pt unknown
-
2021
- 2021-02-18 US US17/178,424 patent/US12508297B2/en active Active
- 2021-06-10 CY CY20211100511T patent/CY1124220T1/el unknown
-
2022
- 2022-09-02 JP JP2022140259A patent/JP2022172279A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125792A patent/JP2024156840A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3416675A1 (en) | 2018-12-26 |
| LT3416675T (lt) | 2021-06-25 |
| JP2022172279A (ja) | 2022-11-15 |
| KR20180110127A (ko) | 2018-10-08 |
| EP3957319A1 (en) | 2022-02-23 |
| JP2019505553A (ja) | 2019-02-28 |
| US12508297B2 (en) | 2025-12-30 |
| EP3416675A4 (en) | 2020-01-08 |
| JP2024156840A (ja) | 2024-11-06 |
| US10953072B2 (en) | 2021-03-23 |
| CY1124220T1 (el) | 2022-05-27 |
| HRP20210862T1 (hr) | 2021-09-17 |
| PT3416675T (pt) | 2021-06-14 |
| JP7674628B2 (ja) | 2025-05-12 |
| SI3416675T1 (sl) | 2021-09-30 |
| US20210228686A1 (en) | 2021-07-29 |
| ES2874592T3 (es) | 2021-11-05 |
| DK3416675T3 (da) | 2021-06-14 |
| ES3008560T3 (en) | 2025-03-24 |
| SMT202100335T1 (it) | 2021-07-12 |
| US20190111110A1 (en) | 2019-04-18 |
| RS61944B1 (sr) | 2021-07-30 |
| HUE055343T2 (hu) | 2022-05-28 |
| EP3416675B9 (en) | 2021-07-14 |
| WO2017143253A1 (en) | 2017-08-24 |
| CN108883156A (zh) | 2018-11-23 |
| EP3416675B1 (en) | 2021-03-24 |
| EP3957319B1 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3416675T (pt) | Tratamento de infeção pelo vírus da hepatite delta com interferão lambda | |
| IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
| ZA201806651B (en) | Elimination of hepatitis b virus with antiviral agents | |
| IL245436A0 (en) | New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection | |
| IL246449A0 (en) | 6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection | |
| IL280869A (en) | Treatment of hepatitis delta virus infection with Lambda interferon | |
| ZA201507840B (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| ZA201900156B (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| SI3137078T1 (sl) | Zdravljenje okužbe s hepatitis delta virusom | |
| HUE054191T2 (hu) | A hepatitis delta vírusfertõzés kezelése | |
| IL249660B (en) | Methods for treating hepatitis b virus and hepatitis d virus infections | |
| IL255366A0 (en) | Reagents for the treatment of hepatitis B infection and their use | |
| EP3226973A4 (en) | Treatment of hepatitis delta virus infection | |
| IL271491A (en) | Treatment of carcinoma of the liver characterized by hepatitis B virus infection | |
| IL286484B (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| AU2015901617A0 (en) | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof | |
| HK40005312A (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| HK40002518A (en) | Elimination of hepatitis b virus with antiviral agents |